Pfizer sells Icagen drug discovery, not compounds
This article was originally published in Scrip
Executive Summary
Four years after Pfizer acquired Icagen for $56m, the big pharma sold the drug discovery firm to XRpro Sciences for up to $11m, which would seem to be a big discount if the deal gave the buyer access to compounds generated by Icagen's ion channel biology platform.
You may also be interested in...
Ligand Buys Into Ongoing Partnerships With Icagen Deal
Ligand gets ongoing drug development collaborations with Roche and CFF, six novel preclinical compounds and sodium ion channel technology platform capabilities in acquiring Icagen’s North Carolina operations.
Finance Watch: 2021 Now Has More IPOs Than 2020, But With $3.2bn Less
Public Company Edition: It took 256 days for 2021 to surpass the 2020 record of 86 biopharma initial public offerings in the US in one year. Also, Procaps raised $115m ahead of its SPAC merger and aTyr and bluebird raised $75m each.
First Lumakras Combo Data Show Boosted Efficacy For Amgen Drug In CRC
Amgen’s KRAS G12C inhibitor in combination with the company’s Vectibix generated a 27% overall response rate, nearly tripling the responses seen with Lumakras monotherapy in colorectal cancer.